Solution for infusion 40mg/2ml, 100mg/5ml, 300mg/15ml
Irinotecan medac is indicated for the treatment of patients with advanced colorectal cancer
- as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.
- in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease.
Irinotecan medac in combination with cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy.
Irinotecan medac in combination with 5-fluorouracil, folinic acid and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.